In last fifteen years with the rapid developments in medicine and technology, genetic material called extra-cellular free fetal DNA of the baby has been examined in the maternal (mother’s) bloodstream. Extracellular cell free fetal DNA is in the form of small particles and circulates freely in the maternal bloodstream. At this time, studies have been intensified and since 2012, cell free fetal DNA has entered the clinical practice for the detection of chromosomal abnormalities.
Cell-free foetal DNA can be defined as the DNA of the foetus that is observed in a pregnant woman’s bloodstream after the 5th week of gestation. This is because of the breakdown of placental cells and this causes the genetic material of the foetus constantly being released into maternal bloodstream. Cell-free foetal DNA is outside the maternal cells in tiny particles and it streams freely in maternal blood. Fetal fraction rate ( The ratio of cell-free foetal DNA in maternal blood) is about 10% in between the 11th and 13th weeks of gestation. This ratio increases as pregnancy proceeds and is normally in between 3% to 20%.
Detection of chromosomal disorders can be performed by analyzing cell free fetal DNA from maternal blood and this method is accepted as screening test which called as ‘’Non-invasive Prenatal Screening Test’’ or Non-invasive Prenatal Test ” shortly called NIPT.
NIPT has been developed from the pre-existing non-invasive prenatal tests like serum screens and vasive techniques. In DNA-based molecular genetics studies, it is proved that several foetal trisomy risks can be determined with NIPT by maternal blood which makes NIPT a practical and reliable DNA test. On the other hand, chorionic villus biopsy (CVB) and amniocentesis requires penetrance to the womb; which increases the risk of miscarriage. NIPT does not have this risk for the baby and the mother since penetrance to the womb is not required and only 9 ml maternal blood is enough to examine the test.
In NIPT, there is no risk of losing the fetus due to the intervention.
NIPT is generally used as a screening test for the detection of chromosome abnormalities that occur in a higher frequency; such as Trisomy 21 (T21), Trisomy 18 (T18), and Trisomy 13 (T13) where the accuracy of NIPT is about 99,9%.
If the test result comes out as negative, it means that the foetus does not have any disorders related to test’s extent and pregnancy proceeds. If the test comes out as positive, the result is confirmed with amniocentesis or cordocentesis before ending pregnancy.
Before the application of NIPT to the mother, the parents should be informed that; NIPT is applied only in the detection of T21, T18, T13 and sex chromosomes (not for twin) abnormalities and according to the clinical applications NIPT is not expected to detect other chromosomal abnormalities such as; other trisomies, monosomies, translocations, insertions, deletions and microdeletions. If the result of the test is positive the result should be further confirmed with amniocentesis and this information should be given to families with genetic counselling and the written consent form has to be signed for the test.
Since NIPT is a genetic test, it should be applied only in genetic centers for genetic diseases with a licence for DNA tests. The authority of drawing and sending blood for NIPT should only belong to such centers. If this test is applied in places other than such centers, the Ministry of Health should warn such companies.
Although the NIPT test is recommended for all pregnant women, it should be applied in cases like;
NIPT test should be done by every mother who wants to have a healthy child and to have a healthy pregnancy process, NIPT test should only be done under the control of licensed genetic assessment centers.
With NIPT test, along with autosomal chromosomal abnormalities (such as Trisomy 21, Trisomy 18, and Trisomy 13), abnormalities in sex chromosomes (Turner Syndrome, Klinefelter Syndrome, XYY Syndrome, and Triple X Syndrome) can also be detected.
Standard NIPT Panel: 21,18,13,X,Y
Wide NIPT Panel: All Chromosomes, additionally microdeletion & microduplication syndromes analyzed.
For more detailed information and for your NIPT requests please contact with our center.
More Information!